ClinicalTrials.gov
ClinicalTrials.gov Menu

Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes (GLUCONEO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02072551
Recruitment Status : Unknown
Verified April 2016 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was:  Active, not recruiting
First Posted : February 26, 2014
Last Update Posted : April 18, 2016
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The main objective of this study is to evaluate Beta cells in patients with a neonotal diabetes linked to a genetic abnormality Metabolic caracteristics will described using a transversal cohort study.

Condition or disease
Diabetes

Study Type : Observational
Actual Enrollment : 17 participants
Time Perspective: Prospective
Official Title: Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal
Study Start Date : December 2012
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Adult with neonatal diabetes
Adult with neonatal diabetes (before 1 year ) and need for insulin
non diabetic adults with a relative with neonatal diabetes



Primary Outcome Measures :
  1. Mean insulin secretion output [ Time Frame: Week after inclusion ]

Secondary Outcome Measures :
  1. insulin secretion outout after arginine perfusion [ Time Frame: during hospitalisation (3 days) ]
  2. sensitivity to insulin [ Time Frame: during hospitalisation (3 days) ]
  3. glucago secretion output [ Time Frame: during hospitalisation (3 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
diabetic people
Criteria

Inclusion Criteria:

  • Age : 18 à 65 year
  • diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline or patient with a relative having neonatal diabetis

Exclusion Criteria:

Diabète induit (médicaments - ex corticoïdes) ou syndromique

  • infection
  • cancer
  • pegnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02072551


Locations
France
Hopital Siant-louis
Paris, France, 75010
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02072551     History of Changes
Other Study ID Numbers: GLUCONEO
First Posted: February 26, 2014    Key Record Dates
Last Update Posted: April 18, 2016
Last Verified: April 2016